Previous Article | Next Article 
Journal of Virology, January 2001, p. 107-114, Vol. 75, No. 1
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.1.107-114.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Molecular Analysis of the Abnormal Prion Protein
during Coinfection of Mice by Bovine Spongiform Encephalopathy
and a Scrapie Agent
Thierry G. M.
Baron1,* and
Anne-Gaelle
Biacabe1,2
Agence Française de
Sécurité Sanitaire des Aliments1 and
Hôpital Neurologique de Lyon,2
Lyon, France
Received 24 August 2000/Accepted 2 October 2000
 |
ABSTRACT |
Molecular features of the proteinase K-resistant prion protein (PrP
res) may discriminate among prion strains, and a specific signature
could be found during infection by the infectious agent causing bovine
spongiform encephalopathy (BSE). To investigate the molecular basis of
BSE adaptation and selection, we established a model of coinfection of
mice by both BSE and a sheep scrapie strain (C506M3). We now show that
the PrP res features in these mice, characterized by glycoform ratios
and electrophoretic mobilities, may be undistinguishable from those
found in mice infected with scrapie only, including when mice were
inoculated by both strains at the same time and by the same
intracerebral inoculation route. Western blot analysis using different
antibodies against sequences near the putative N-terminal end of PrP
res also demonstrated differences in the main proteinase K cleavage
sites between mice showing either the BSE or scrapie PrP res profile.
These results, which may be linked to higher levels of PrP res
associated with infection by scrapie, were similar following a
challenge by a higher dose of the BSE agent during coinfection by both
strains intracerebrally. Whereas PrP res extraction methods used
allowed us to distinguish type 1 and type 2 PrP res, differing, like
BSE and scrapie, by their electrophoretic mobilities, in the same brain
region of some patients with Creutzfeldt-Jakob disease, analysis of in
vitro mixtures of BSE and scrapie brain homogenates did not allow us to
distinguish BSE and scrapie PrP res. These results suggest that the BSE
agent, the origin of which remains unknown so far but which may have
arisen from a sheep scrapie agent, may be hidden by a scrapie strain
during attempts to identify it by molecular studies and following
transmission of the disease in mice.
 |
INTRODUCTION |
The bovine spongiform encephalopathy
(BSE) agent may have originated from a scrapie agent infecting small
ruminants, which would have been recycled through cattle and
disseminated through the use of contaminated meat and bonemeal. It is
assumed to have caused prion diseases not only in cattle but also in a
variety of other species, such as domestic cats and some exotic felines and ruminants (7). Strong evidence indicates that the
recently described variant Creutzfeldt-Jakob disease (vCJD) is due to
the same agent as well (7), which could also have infected
other species in field conditions, such as sheep or goats
(8).
The ultimate evidence that infectious agents from different isolates
are identical eventually requires transmission of the disease in mice
and characterization of the lesion profiles in the brain. Such
experiments reveal the existence of a number of different "strains"
in natural scrapie from sheep and goats, but it is unknown to what
extent these mouse-adapted scrapie strains, with different behavior in
mice, are representative of field scrapie strains (6).
During the isolation of strains by transmission in mice from a
particular isolate, even when the disease features have stabilized in
the new host, a mixture of minor strains and a major strain can also be
stably passaged, and some changes may then occur following cloning of
the major strain by limiting dilution (6). In cattle, a
single strain or a limited number of strains with a very stable and
uniform behavior in mice have been recognized so far in each case
analyzed at different times during the epidemic and from widely
separated locations (6, 15).
It has also been found that qualitative and quantitative analysis of
the different glycoforms of the proteinase K-resistant prion protein
(PrP res), detected by Western blotting, showed a consistent and unique
pattern in BSE-linked diseases, as in experimentally infected macaques
or mice and in naturally infected domestic cats, as well as in
humans developing vCJD (9, 16). Such features also allowed
different mouse-adapted scrapie strains to be distinguished
(20, 25, 33). These findings, which may result from
strain-specific differences in PrP res conformation, argue for a link
between the molecular features of the protease-resistant prion
protein and strain variation (32, 36).
Regarding the molecular features of PrP res in sheep, a species from
which the BSE strain may have emerged, very uniform features have been
described in some studies between different isolates from various
geographical locations (3, 35). In contrast, a variety of
PrP res patterns have also been reported in a few natural and
experimental scrapie cases, which was believed to reflect a high
diversity of field sheep scrapie strains (17, 19). In a
particular experimental sheep scrapie strain (CH 1641), close
similarities with the PrP res pattern of BSE in sheep was found
(2, 19).
We now report that following infection of mice by both scrapie and BSE
strains, the molecular features of PrP res may be indistinguishable from those found in mice infected by scrapie alone, whereas the analysis of in vitro mixtures of scrapie and BSE brain homogenates also
suggest that a scrapie PrP res pattern can be found despite the
presence of PrP res associated with the BSE agent.
 |
MATERIALS AND METHODS |
Animals and agent strains.
The murine scrapie strains used
in this study were C506M3 (kindly provided by D. Dormont, Commissariat
à L'Energie Atomique, Fontenay-aux-Roses, France) and Chandler
and 79A (kindly provided by M. Bruce, Institute of Animal Health,
Edinburgh, United Kingdom). The BSE strain was isolated from a French
cattle BSE case. These strains were routinely maintained by serial
passage into C57BL/6 mice (IFFA Credo) by intracerebral inoculation of
1% (wt/vol) brain homogenate in 5% glucose in distilled water (20 µl per animal) from brains sampled at the terminal stage of the disease.
For coinfection of mice by both BSE and scrapie, the C506M3 scrapie
strain was chosen. Coinfections were performed by intracerebral (20 µl of brain homogenate per animal) or intraperitoneal (100 µl of
brain homogenate per animal) inoculation of both scrapie and BSE
strains in the same animals, as described in Table
1. For molecular studies of coinfected
animals, Western blot analysis was performed on samples from three
different animals per experimental group from brains sampled at the
terminal stage of the disease.
Cases of Creutzfeldt-Jakob disease.
Thirty-two
patients with clinical Creutzfeld-Jakob disease were
characterized by Western blot analysis of brain tissue. The frontal
cortex, striatum, and cerebellum were studied from each patient when
available as frozen tissues.
Extraction of PrP res.
PrP res was obtained by two different
methods. The first method, previously described for sheep PrP res
typing (3), involved PrP res concentration by
ultracentrifugation. Dissociation of half of the whole brain of mice or
equivalent quantities of brain material from humans was performed in 1 ml of 5% glucose in distilled water, using disposable blenders, and
complete homogenization was obtained by forcing the brain suspension
through a 0.4-mm-diameter needle. A 330-µl volume was brought up to
1.2 ml in 5% glucose before incubation with proteinase K (20 to 25 µg/100 mg of brain tissue) (Roche) for 1 h at 37°C.
N-Lauroyl sarcosyl (30%; 600 µl) (Sigma) was added. After
incubation at room temperature for 15 min, samples were centrifuged at
465,000 × g for 2 h on a 10% sucrose cushion in
a Beckman TL100 ultracentrifuge. Pellets were resuspended and heated
for 5 min at 100°C in 50 µl of denaturing buffer (4% sodium
dodecyl sulfate [SDS], 2%
-mercaptoethanol, 192 mM glycine, 25 mM
Tris, 5% sucrose).
A second method involved direct search for PrP res in brain homogenates
without any ultracentrifugation step, as previously
described for PrP
res typing in Creutzfeldt-Jakob disease (
9).
After
homogenization in 5% glucose and proteinase K digestion
as previously
described, the digestion was stopped by the addition
of Pefabloc
(Roche) to a 1 mM final concentration. Then, the sample
was mixed with
the same volume of denaturing buffer, heated for
5 min at 100°C, and
centrifuged at 12,000 ×
g for 10 min. Supernatants
were then collected for further studies by SDS-polyacrylamide
gel
electrophoresis
(PAGE).
For analysis of in vitro mixtures of BSE and scrapie, brain homogenates
of each strain were mixed in different proportions
before treatment by
proteinase K and ultracentrifugation. Samples
corresponding to
different ratios of BSE and scrapie PrP res were
then analyzed and
compared to BSE or scrapie alone by Western
blot
analysis.
Western blot analysis.
Samples were run in SDS-15% PAGE
and electroblotted to nitrocellulose membranes in transfer buffer (25 mM Tris, 192 mM glycine, 10% isopropanol) at a constant 400 mA for
1 h. The membranes were blocked for 1 h with 5% nonfat dried
milk in phosphate-buffered saline (PBS)-0.1% Tween 20 (PBST). After
two washes in PBST, for mouse PrP res studies, membranes were incubated
(1 h at room temperature) with RB1 rabbit antiserum (1:2,500 in PBST)
raised against synthetic bovine (THGQWNKPSKPKTNMK) PrP peptide
(28) or SAF15 monoclonal antibody (kindly provided by J. Grassi, SPI/CEA, Saclay, France). SAF15 was prepared against formic
acid-treated hamster SAFs and shown to recognize the 79-92 human PrP
sequence. For human PrP res studies, 3F4 monoclonal antibody (Senetek)
(1:5,000 in PBST) was used (21). After three washes in
PBST, the membranes were incubated (30 min at room temperature) with
peroxidase-labeled conjugates against rabbit or mouse immunoglobulins
(1:2,500 in PBST) (Clinisciences). After three washes in PBST, bound
antibodies were then detected by enhanced chemiluminescence (Amersham)
or Supersignal (Pierce) chemiluminescent substrates. For quantitative studies of the glycoform ratios, chemiluminescent signals corresponding to the three glycoforms of the protein were quantified using a Fluor
S-Multimager (Bio-Rad) analysis system. Glycoform ratios were expressed
as mean percentages ± standard errors of the total signal for the
high (H), low (L), and unglycosylated (U) glycoforms obtained from
three mice per experimental group and at least five separate gel runs
per sample. Migrations of the unglycosylated PrP res were compared on
films after exposure of the membranes on Biomax MR Kodak films (Sigma)
from repeated runs of the samples. After preliminary experiments, loads
of samples per lane were adjusted for comparison between the different
animal groups, to provide the best comparison of electrophoretic
mobilities, but in experiments that were specifically designed to
compare the levels of PrP res accumulation in brain.
Deglycosylation of PrP res.
For deglycosylation of PrP res,
pellets obtained following proteinase K treatment and
ultracentrifugation from brain homogenates were denatured by heat
treatment at 100°C for 10 min in 50 µl of 0.5% SDS in distilled
water. After addition of 200 µl of 0.5% Triton X-100 in 50 mM
Tris-HCl (pH 8.0)-5 mM phenylmethylsulfonyl fluoride, the samples were
treated by PNGase F (Roche) (1 U/sample) and incubated at 37°C
overnight. Proteins were then precipitated in ethanol and finally
resuspended in 50 µl of denaturing buffer before analysis by SDS-PAGE
as previously described.
 |
RESULTS |
Glycoform profiles of PrP res in BSE and scrapie strains.
The
glycoform ratios in BSE and the three scrapie strains C506M3, Chandler,
and 79A could be distinguished, as shown in Fig. 1A, especially showing high levels of
diglycosylated protein and low levels of unglycosylated protein in BSE.
In both 79A and Chandler strains, the monoglycosylated PrP res was the
most abundant species, whereas the C506M3 strain had intermediate
features compared to BSE and to these last scrapie strains and showed
comparable levels of di- and monoglycosylated protein.

View larger version (78K):
[in this window]
[in a new window]
|
FIG. 1.
Proportions of PrP res glycoforms (A) and comparison of
electrophoretic mobilities (B) in BSE- and scrapie-infected mice after
Western blot analysis using RB1 antiserum. Proportions of glycoforms
are expressed as arithmetical means ± standard error of
high-glycosylation (H), low-glycosylation (L), and unglycosylated (U)
PrP res. Animal groups: 1, BSE; 2, C506M3 scrapie strain; 3, Chandler
scrapie strain; 4, 79A scrapie strain.
|
|
Regarding the apparent molecular mass of the unglycosylated PrP res,
among these four strains, that from BSE also had a specifically
lower
molecular mass than that from the three different scrapie
strains (Fig.
1B).
Glycoform profiles following coinfection of mice by BSE and
scrapie.
For studies of the PrP res patterns of animals coinfected
by BSE and scrapie, we inoculated mice with a mixture of brain
homogenates from C506M3 and from BSE-infected terminally ill mice. We
studied PrP res at the terminal stage of the disease in three mice per experimental group of BSE- and scrapie-coinfected mice (176 to 212 days postinoculation).
The results of the glycoform analysis in mice infected with both
strains showed that only mice inoculated with BSE by the
intracerebral
route and intraperitoneally with scrapie (group
4) had a profile
similar to that found in mice infected with BSE
only (group 1) (Fig.
2), with no statistically significant
differences
in the glycoform ratios at the 5% level. On the other
hand, mice
inoculated by both BSE and scrapie by the same intracerebral
route
(group 2), as well as mice inoculated intracerebrally by scrapie
and intraperitoneally by BSE (group 5), did not show statistically
significant differences in the glycoform ratios (at the 5% level)
from
mice inoculated with scrapie only (group 6). In contrast,
experimental
groups 1 and 4 (BSE profile) were highly significantly
different from
groups 2, 5, and 6 (scrapie profile) (
P = 0.005
and
0.004 for the diglycosylated and monoglycosylated forms, respectively).
These differences between groups with a BSE profile (1 and 4)
and those
with a scrapie profile (2, 5, and 6) were assessed not
only by studies
of the glycoform ratios (Fig.
2) but also by analysis
of the
electrophoretic mobilities of the unglycosylated PrP res
(Fig.
3). They were also confirmed by
comparison of the molecular
masses of PrP res after deglycosylation by
PNGase (Fig.
4).

View larger version (75K):
[in this window]
[in a new window]
|
FIG. 2.
Proportions of mouse PrP res glycoforms after Western
blot analysis using RB1 antiserum. Proportions of glycoforms are
expressed as arithmetical means ± standard error of
high-glycosylation (H), low-glycosylation (L), and unglycosylated (U)
PrP res. Groups were inoculated as described in Table 1.
|
|

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 3.
Western blot analysis of mouse PrP res detected using
RB1 antiserum. Animal groups were inoculated as described in Table 1.
|
|

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 4.
Western blot analysis of mouse PrP res detected using
RB1 antiserum following deglycosylation by PNGase F. Groups were
inoculated as described in Table 1.
|
|
In order to evaluate the possible influence of PrP res extraction
methods, we analyzed PrP res directly detected from brain
homogenates,
as previously described for PrP res typing in human
Creutzfeld-Jakob
disease (
9), rather than SAF preparation by
ultracentrifugation. Similar results were obtained with this method
(Fig.
5b). Furthermore, these experiments
allowed a direct comparison
of PrP res detection following loading of
similar quantities of
brain material per lane in SDS-PAGE (Fig.
5a,
with 0.5 mg of brain
equivalent per lane). Mice inoculated with BSE
only intracerebrally
(group 1) or with BSE intracerebrally and scrapie
intraperitoneally
(group 4) had the lowest levels of PrP res; other
groups of mice
(groups 2, 5, and 6), which otherwise had a scrapie PrP
res pattern,
had higher levels of PrP res.

View larger version (106K):
[in this window]
[in a new window]
|
FIG. 5.
Western blot analysis of mouse PrP res directly detected
from brain homogenates using RB1 antiserum. Animal groups are defined
in Table 1. Brain equivalents loaded per lane: (a) 0.5 mg; (b) from
left to right, 0.6, 0.25, 0.25, 0.5, and 0.2 mg.
|
|
In a separate experiment, we challenged mice by both strains
intracerebrally (group 3) but with a higher (20×) dose of the
BSE
strain in the inoculum (20% BSE-infected brain homogenate)
mixed with
the scrapie strain (1% scrapie-infected brain homogenate).
In this
case again, we could not detect any difference in the
electrophoretic
mobility of the unglycosylated protein when we
compared these mice to
animals infected with scrapie only (group
6); the apparent molecular
mass also appeared to be clearly distinguishable
from and higher than
that in mice infected with BSE only (group
1) (Fig.
3, lane
3).
Molecular analysis of in vitro mixtures of BSE and scrapie.
We
then analyzed PrP res extracted from in vitro mixtures of C506M3 and
BSE brain homogenates in different proportions. As shown in Fig.
6, these studies revealed that the
unglycosylated protein always appeared as a single band, as previously
found in BSE- and scrapie-coinfected mice. The electrophoretic mobility depended upon the proportions of scrapie and BSE; nevertheless, it
decreased rapidly close to that found in scrapie as soon as the
quantity of scrapie brain material increased. Similar results, showing
a single band for unglycosylated PrP res, were also obtained following
Western blotting of BSE and scrapie PrP res mixed after separate
extractions of the two strains and mixtures of the proteins after their
denaturation (data not shown). In a 20:1 BSE-C506 mixture, a single
band with a size intermediate between those observed in BSE and scrapie
was detected (Fig. 6, lane 2).

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 6.
Western blot analysis of in vitro mixtures of mouse PrP
res from scrapie and BSE strains using RB1 antiserum. Lane 1, BSE
alone. Lanes 2 to 6, BSE-scrapie ratios of 20:1, 10:1, 5:1, 2:1, and
1:1, respectively.
|
|
Analysis of PrP res proteinase K cleavage sites by antigenic
mapping.
Since different fragment sizes of PrP res were observed
for scrapie and BSE, we further compared mice infected with BSE or strain C506M3 only or with both strains, using antibodies acting near
the expected proteinase K cleavage site (10, 18). We used
RB1 antiserum and SAF15 monoclonal antibody directed against sequences
corresponding to residues 94 to 109 and 78 to 91 of the murine PrP, respectively.
We first loaded comparable quantities of PrP res per lane, as
recognized by RB1 antiserum after quantification of the samples
with
the Fluor-S MultiImager (Fig.
7A). Using
SAF15 monoclonal
antibody to detect PrP res from samples run in
duplicate gels,
we then found quite a lower reactivity in mice infected
with BSE
only (group 1) (Fig.
7B, lane 1) or following coinfection by
BSE
intracerebrally and by scrapie intraperitoneally (group 4) (Fig.
7B, lane 3). The results thus showed a clear relationship between
intensity of labeling by SAF15 antibody and electrophoretic mobilities;
samples with a higher apparent molecular mass, corresponding to
a
scrapie PrP res profile (groups 2, 5, and 6), are better recognized
by
SAF15 antibody than those showing a BSE PrP res profile.

View larger version (76K):
[in this window]
[in a new window]
|
FIG. 7.
Western blot analysis of mouse PrP res using RB1
antiserum (A) or SAF15 monoclonal antibody (B and C). Animal groups are
defined in Table 1. (B) Lanes were loaded with comparable levels of PrP
res, as determined by using RB1 antibody. (C) The first and third lanes
were overloaded.
|
|
Overloading (5- to 10-fold) of samples with the lower molecular mass
(samples with BSE PrP res profiles), however, showed
labeling of all
samples by SAF15 antibody, but no differences
could then be detected in
the PrP res fragment sizes between the
different samples (Fig.
7C)
compared to those previously observed
using RB1 antibody (Fig.
7A).
Studies of Creutzfeldt-Jakob disease with type 1 and type 2 PrP
res.
As a control for the ability of the methods used in this
study to discriminate PrP res differing in electrophoretic mobility from the same tissue, we chose to seek Creutzfeldt-Jakob disease with
occurrence of both type 1 and type 2 PrP res in the same brain
(31). Among a series of 32 Creutzfeld-Jakob disease cases which were studied by Western blotting, we found 2 in which both type 1 and type 2 PrP res could clearly be distinguished in cortical regions
of the brain (Fig. 8, lane 3).

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 8.
Western blot analysis of PrP res in humans with
Creutzfeld-Jakob disease using 3F4 monoclonal antibody. Lane 1, type 1 PrP res; lane 2, type 2 PrP res; lane 3, co-occurrence of type 1 and
type 2 PrP res in the cortex of the same patient; lane 4, brain region
of the same patient showing only type 1 PrP res.
|
|
 |
DISCUSSION |
We report that following inoculation of mice by both scrapie and
BSE strains previously adapted by serial transmission to mice, the PrP
res glycoprofiles may appear to be undistinguishable from those found
in mice infected with scrapie only (group 6), including mice infected
by BSE and scrapie at the same time and by the same inoculation route
(groups 2 and 3). These results were obtained using the C506M3 strain,
which appeared, as previously described for other murine scrapie
strains (25, 33; this study), to be easily
distinguishable from BSE in mice. Characterization of the scrapie
strains in this study fit with data previously described, generally
reporting a specifically lower molecular mass of the unglycosylated PrP
res following infection by the BSE agent (9, 10, 16, 17,
24). The glycoform ratios and the electrophoretic mobilities of
unglycosylated PrP res following inoculation of both strains were
similar to those found in scrapie-inoculated mice (group 6) when both
BSE and scrapie were inoculated into the brain (groups 2 and 3) or when
scrapie was inoculated intracerebrally and BSE intraperitoneally (group
5). The BSE profile was only observed when BSE alone was inoculated
into the brain (groups 1 and 4), including mice inoculated by scrapie
intraperitoneally at the same time (group 4).
These features were further characterized by evidence of differential
reactivity of a monoclonal antibody (SAF15) that recognizes residues 78 to 91 of murine PrP compared to antiserum RB1, directed against
residues 94 to 109. The epitope recognized by SAF15 antibody appeared
to be digested by proteinase K in a larger proportion of PrP res
molecules specifically in mice showing a BSE PrP res profile (groups 1 and 4). Distinct proteinase K cleavage sites between different strains
have already been demonstrated in some experimental models, such as
transmissible mink encephalopathy transmitted to hamster
(30), and in some natural diseases, such as
Creutzfeldt-Jakob disease (1), by antigenic mapping
(5) or by amino-terminal sequencing (1, 30).
A subset of PrP res molecules is, however, recognized by SAF15 antibody
in mice with the BSE PrP res profile (groups 1 and 4), in line with
previous data showing ragged amino-terminal cleavage by proteinase K
(18, 34).
It is also noteworthy that, in our studies, during the analysis of in
vitro mixtures of brain homogenates from mice infected with BSE and
C506M3, necessarily containing BSE infectivity at this stage, the BSE
profile could be easily hidden by the addition of brain homogenate from
scrapie-infected mice. Whatever the proportions of BSE and scrapie were
in the mixtures, we could not separately identify scrapie and BSE PrP
res, as in mice infected with both strains, but in some cases we
observed an intermediate banding pattern (BSE-scrapie ratio, 20:1). In
this respect, these results are in line with those described during
coinfection by DY and HY hamster strains from transmissible mink
encephalopathy, showing some cases with an intermediate banding pattern
between the 19- and 21-kDa PrP res patterns specific for the two
strains (4). However, in vivo, we did not find such an
intermediate banding pattern, including after inoculation of a high
load of BSE (ratio, 20:1), but a scrapie PrP res profile was then
observed, consistent with a specific increase in scrapie-associated PrP
res during in vivo replication. In contrast, we confirmed in two cases
of Creutzfeldt-Jakob disease that type 1 and type 2 PrP res with distinct fragment sizes could be detected separately in some brain regions of the same patients (13, 31). This result has
been obtained both following direct detection of PrP res from brain homogenates (9) and in SAF preparations (3),
whereas these two methods failed to distinguish scrapie and BSE PrP res
in mice coinfected with both strains. However, with respect to such
cases of Creutzfeldt-Jakob disease, the occurrence of both types of PrP
res has been shown to be associated with different
histopathological features (diffuse deposits or plaques) that may
modify the accessibility of the amino-terminal end of PrP res
(10, 31). The specific features of these two different
abnormal PrPs which are accumulating in the brain of some patients at
separate locations and with distinct morphological features could also
be associated with their propensity to migrate separately, without
mixing together, during SDS-PAGE. Whether these behaviors are
associated with PrP alone or some other unidentified associated factors
present in the brain is presently unknown.
It was previously shown that PrP res was more abundant in the brain of
C506M3-inoculated C57BL/6 mice than in BSE-infected mice but that both
strains, which otherwise had comparable incubation periods in C57BL/6
mice (about 180 days after intracerebral inoculation), were
characterized by similar infectious titers at the terminal stage of the
disease (26). More generally, the PrP res levels produced
by a given strain appeared as a specific feature that could
differentiate strains, without any apparent relationship with the
duration of the incubation period (32). The PrP res levels
detected in mice in our study indeed were higher in mice with a scrapie
PrP res profile, as assessed in experiments in which equal quantities
of brain material were compared between mice belonging to different
experimental groups. The results of PrP res characterization are thus
consistent with a pattern essentially determined by the more abundant
PrP res species accumulating in the brain at the time of death of the
animal. Following intraperitoneal inoculation of one of the strains,
the level of PrP res produced by this particular strain in the brain is
expected to be low at the time that mice die if they were inoculated at
the same time with the other strain by the intracerebral route
(26), leading to a PrP res pattern essentially determined
by this intracerebrally inoculated strain. Following intracerebral
inoculation of both strains, the proportion of BSE-associated PrP res
may be too low to be detected. However, some molecular changes of this
abnormal PrP itself during its accumulation together with
scrapie-associated PrP res cannot be excluded.
These results were obtained following inoculation of mouse-adapted
strains. The behavior of a mixture of scrapie and BSE from ruminant
isolates during a primary passage in the mouse is unknown. With respect
to PrP res accumulation in brain, some experiments have reported
undetectable levels of PrP res in mice infected with BSE from cattle,
at least in a mouse line (C57BL/6) (27). On the other
hand, it was reported that the success rate of transmission of natural
scrapie isolates in mice varied enormously (6).
Further experiments by transmission into mice and characterization of
the distribution of brain lesions are required to characterize the
infectious agent detected in the brain of mice infected with both
scrapie and BSE strains. It cannot be excluded that during coinfection,
the replication of the BSE agent had been hampered by that of scrapie.
Competition between two strains has already been described, one
inoculated "slow" strain being able to prevent infection by another
more rapid strain that was inoculated later in the same animal, but
competition only occurred when the two strains were inoculated at
sufficient time intervals (11, 12, 22). However, in our
experiments, the two strains were characterized by similar incubation
periods and had been inoculated simultaneously. Furthermore, in some of
our experiments, a higher load of BSE brain homogenate in the inoculum
compared to scrapie has been used to challenge mice with both strains
by the intracerebral route (group 3) in order to evaluate the
possibility of competition between strains at the very early phase of
infection. The PrP res profiles at the terminal stage of the disease
were again similar to those found in mice infected with scrapie only
(group 6). Such competition could also occur when both strains are
inoculated, each of them by different routes (intracerebral or
intraperitoneal), the intraperitoneal inoculation route being
associated with a longer incubation period and a delayed accumulation
of PrP res in brain. However, the profile of brain PrP res following
intracerebral inoculation of one strain was not significantly modified
following simultaneous inoculation of the other strain intraperitoneally.
Separation from a mixture of agent strains through serial passage in
hamster that led to strains with distinct transmissibility to mice has
been described, the dose of each strain being likely able to influence
the outcome of transmission (23). In a study of
transmissible mink encephalopathy transmitted to a hamster, it has also
been shown that two different PrP res, 19 and 21 kDa, corresponding to
two different strains (DY and HY, respectively), could be selected from
a mixture through serial passage in hamsters according to the brain
dilution inoculum used (4). Adaptation and selection of
the strain with the shortest incubation period (HY) could occur after
serial intraspecies passage, even though it was initially present at
lower doses. Following coinfection by both HY and DY strains, a
reversion from the DY to the HY strain phenotype could be observed when
hamsters were coinfected with brain dilutions of 10
7 and
10
2, respectively. The PrP res strain-specific patterns
preceded the stabilization of strain phenotypes, whose emergence could be predicted.
Regarding the molecular features of PrP res in natural scrapie,
conflicting results have been reported (3, 17, 19, 29,
35). It was recently reported that a single experimental scrapie
strain, CH1641, isolated from a natural scrapie case in 1971 in the
United Kingdom (14), had similar molecular features to
those found in experimentally BSE-infected sheep, particularly with
respect to the identical fragment sizes of the unglycosylated PrP res
(19). No other natural scrapie case has ever displayed features identical to those found in experimentally BSE-infected sheep
(2, 17, 19). The propensity to accumulate PrP res in brain
in sheep infected with BSE, compared to scrapie, is unknown, but in
some cases Western blot analysis failed to detect PrP res in
experimentally BSE-infected sheep (17). Whereas our
experiments involved mice infected with a mouse-adapted strain, the
outcome of infection in sheep infected by both BSE and scrapie strains may also be different. However, it was reported that different scrapie
strains could be isolated from a single natural scrapie case by
transmission in mice (6). Mixtures of PrP res bearing distinct molecular and pathogenic properties could be present in
individual sheep as well, which could explain at least partly the
homogeneous PrP res profiles found in a number of scrapie cases
(3, 35). Some mouse-adapted strains with different electrophoretic profiles, such as ME7 and 22A, indeed originated from
the same original source of natural scrapie (33). From such mixtures, a particular strain with distinct molecular and pathogenic features, and especially transmissibility, could emerge after some selection during their transmission, as this possibly happened during recycling of the BSE agent in contaminated protein supplements from ruminants.
Our results demonstrate that identification of a strain by molecular
analysis and mouse transmission studies may in some respects be
misleading, since, if a mixture of several strains is present, the
strains associated with higher levels of PrP res may hide other strains
present at lower levels.
 |
ACKNOWLEDGMENTS |
We gratefully thank A. Kato and D. Canal for their excellent
technical help and S. Philippe for statistical analysis of the data.
This work was partly funded by grants from the European Commission
(proposal PL 97 3305) and the Programme National de Recherches sur les
ESST et les Prions.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: AFSSA-Lyon, 31 ave. Tony Garnier, 69364 Lyon cedex 07, France. Phone: (33) (4)
78-72-65-43. Fax: (33) (4) 78-61-91-45. E-mail:
t.baron{at}lyon.afssa.fr.
 |
REFERENCES |
| 1.
|
Aucouturier, P.,
R. J. Kascsak,
B. Frangione, and T. Wisniewski.
1999.
Biochemical and conformational variability of human prion strains in sporadic Creutzfeldt-Jakob.
Neurosci. Lett.
274:33-36[CrossRef][Medline].
|
| 2.
|
Baron, T. G. M.,
J.-Y. Madec,
D. Calavas,
Y. Richard, and F. Barillet.
2000.
Comparison of French natural scrapie isolates with bovine spongiform encephalopathy and experimental scrapie infected sheep.
Neurosci. Lett.
284:175-178[CrossRef][Medline].
|
| 3.
|
Baron, T. G. M.,
J.-Y. Madec, and D. Calavas.
1999.
Similar signature of the prion protein in natural sheep scrapie and bovine spongiform encephalopathy-linked diseases.
J. Clin. Microbiol.
37:3701-3704[Abstract/Free Full Text].
|
| 4.
|
Bartz, J. C.,
R. A. Bessen,
D. McKenzie,
R. F. Marsh, and J. M. Aiken.
2000.
Adaptation and selection of prion protein strain conformations following interspecies transmission of transmissible mink encephalopathy.
J. Virol.
74:5542-5547[Abstract/Free Full Text].
|
| 5.
|
Bessen, R. A., and R. F. Marsh.
1992.
Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent.
J. Virol.
66:2096-2101[Abstract/Free Full Text].
|
| 6.
|
Bruce, M.
1996.
Strain typing studies of scrapie and BSE, p. 223-236.
In
H. Baker, R. M. Ridley, and N. J. Totowa (ed.), Prion diseases. Humana Press, Clifton, N.J.
|
| 7.
|
Bruce, M. E.,
R. G. Will,
J. W. Ironside,
I. McConnell,
D. Drummond,
A. Suttle,
L. McCardle,
A. Chree,
J. Hope,
C. Birkett,
S. Cousens,
H. Fraser, and C. J. Bostock.
1997.
Transmission to mice indicate that "new variant" CJD is caused by the BSE agent.
Nature
389:498-501[CrossRef][Medline].
|
| 8.
|
Butler, D.
1998.
Doubts over ability to monitor risks of BSE spread to sheep.
Nature
395:6-7[CrossRef][Medline].
|
| 9.
|
Collinge, J.,
K. C. L. Sidle,
J. Meads,
J. Ironside, and A. F. Hill.
1996.
Molecular analysis of prion strain variation and the aetiology of `new variant' CJD.
Nature
383:685-690[CrossRef][Medline].
|
| 10.
|
Demart, S.,
J. G. Fournier,
C. Creminon,
Y. Frobert,
F. Lamoury,
D. Marce,
C. Lasmezas,
D. Dormont,
J. Grassi, and J. P. Deslys.
1999.
New insight into abnormal prion protein using monoclonal antibodies.
Biochem. Biophys. Res. Commun.
265:652-657[CrossRef][Medline].
|
| 11.
|
Dickinson, A. G.,
H. Fraser,
I. McConnell,
G. W. Outram,
D. I. Sales, and D. M. Taylor.
1975.
Extraneural competition between different scrapie agents leading to loss of infectivity.
Nature
253:556[Medline].
|
| 12.
|
Dickinson, A. G.,
H. Fraser,
V. M. H. Meikle, and G. W. Outram.
1972.
Competition between different scrapie agents in mice.
Nat. New Biol.
237:244-245[Medline].
|
| 13.
|
Dickinson, D. W., and P. Brown.
1999.
Multiple prion types in the same brain. Is a molecular diagnosis of CJD possible?
Neurology
53:1903-1904[Free Full Text].
|
| 14.
|
Foster, J. D., and A. G. Dickinson.
1988.
The unusual properties of CH1641, a sheep-passaged isolate of scrapie.
Vet. Rec.
123:5-8[Abstract].
|
| 15.
|
Fraser, H.,
I. Mc Connell,
G. A. H. Wells, and M. Dawson.
1988.
Transmission of bovine spongiform encephalopathy to mice.
Vet. Rec.
123:472-472[Medline].
|
| 16.
|
Hill, A.,
M. Desbruslais,
S. Joiner,
K. C. L. Sidle,
I. Gowland, and J. Collinge.
1997.
The same prion strain causes vCJD and BSE.
Nature
389:448-450[CrossRef][Medline].
|
| 17.
|
Hill, A. F.,
K. C. L. Sidle,
S. Joiner,
P. Keyes,
T. C. Martin,
M. Dawson, and J. Collinge.
1998.
Molecular screening of sheep for bovine spongiform encephalopathy.
Neurosci. Lett.
255:159-162[CrossRef][Medline].
|
| 18.
|
Hope, J.,
G. Multhaup,
L. J. D. Reekie,
R. H. Kimberlin, and K. Beyreuther.
1988.
Molecular pathology of scrapie-associated fibril protein (PrP) in mouse brain affected by the ME7 strain of scrapie.
Eur. J. Biochem.
172:271-277[Medline].
|
| 19.
|
Hope, J.,
S. C. E. R. Wood,
C. R. Birkett,
A. Chong,
M. E. Bruce,
D. Cairns,
W. Goldmann,
N. Hunter, and C. J. Bostock.
1999.
Molecular analysis of ovine prion protein identifies similarities between BSE and an experimental isolate of natural scrapie, CH1641.
J. Gen. Virol.
80:1-4[Abstract].
|
| 20.
|
Kascsak, R.,
R. Rubenstein,
P. A. Merz,
R. Carp,
N. K. Robakis,
H. M. Wisniewski, and H. Diringer.
1986.
Immunological comparison of scrapie-associated fibrils isolated from animals infected with four different scrapie strains.
J. Virol.
59:676-683[Abstract/Free Full Text].
|
| 21.
|
Kascsak, R. J.,
R. Rubenstein,
P. A. Merz,
M. Tonna Demasi,
R. Fersko,
R. I. Carp,
H. M. Wisniewski, and H. Diringer.
1987.
Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins.
J. Virol.
61:3688-3693[Abstract/Free Full Text].
|
| 22.
|
Kimberlin, R. H., and C. A. Walker.
1985.
Competition between strains of scrapie depends on the blocking agent being infectious.
Intervirology
23:74-81[Medline].
|
| 23.
|
Kimberlin, R. H., and C. A. Walker.
1978.
Evidence that the transmission of one source of scrapie agent to hamsters involves separation of agent strains from a mixture.
J. Gen. Virol.
39:487-496[Abstract/Free Full Text].
|
| 24.
|
Kuczius, T., and M. H. Groschup.
1999.
Differences in proteinase K resistance and neuronal deposition of abnormal prion proteins characterize bovine spongiform encephalopathy (BSE) and scrapie strains.
Mol. Med.
5:406-418[Medline].
|
| 25.
|
Kuczius, T.,
I. Haist, and M. H. Groschup.
1998.
Molecular analysis of bovine spongiform encephalopathy and scrapie strain variation.
J. Infect. Dis.
178:693-699[Medline].
|
| 26.
|
Lasmézas, C. I.,
J. P. Deslys,
R. Demaimay,
K. T. Adjou,
J. J. Hauw, and D. Dormont.
1996.
Strain specific and common pathogenic events in murine models of scrapie and bovine spongiform encephalopathy.
J. Gen. Virol.
77:1601-1609[Abstract/Free Full Text].
|
| 27.
|
Lasmézas, C. I.,
J.-P. Deslys,
O. Robain,
A. Jaegly,
V. Beringue,
J.-M. Peyrin,
J.-G. Fournier,
J.-J. Hauw,
J. Rossier, and D. Dormont.
1996.
Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein.
Science
275:402-405[Abstract/Free Full Text].
|
| 28.
|
Madec, J.-Y.,
P. Belli,
D. Calavas, and T. Baron.
2000.
Efficiency of Western blotting for the specific immunodetection of proteinase K-resistant prion protein in BSE diagnosis in France.
Vet. Rec.
146:74-76[Free Full Text].
|
| 29.
|
Madec, J.-Y.,
M. H. Groschup,
D. Calavas,
F. Junghans, and T. Baron.
2000.
Protease-resistant prion protein in brain and lymphoid organs of sheep within a naturally scrapie-infected flock.
Microb. Pathog.
28:353-362[CrossRef][Medline].
|
| 30.
|
Marsh, R. F., and R. A. Bessen.
1994.
Physicochemical and biological characterizations of distinct strains of the transmissible mink encephalopathy agent.
Phil. Trans. R. Soc. Lond. B
343:413-414[CrossRef][Medline].
|
| 31.
|
Puoti, G.,
G. Giaccone,
G. Rossi,
B. Canciani,
O. Bugiani, and F. Tagliavini.
1999.
Sporadic Creutzfeldt-Jakob disease: co-occurrence of different types of PrP Sc in the same brain.
Neurology
53:2173-2176[Abstract/Free Full Text].
|
| 32.
|
Safar, J.,
H. Wille,
V. Itrri,
D. Groth,
H. Serban,
M. Torchia,
F. E. Cohen, and S. B. Prusiner.
1998.
Eight prion strains have PrPSc molecules with different conformations.
Nat. Med.
4:1157-1165[CrossRef][Medline].
|
| 33.
|
Somerville, R. A.,
A. Chong,
O. U. Mulqueen,
C. R. Birkett,
S. C. E. R. Wood, and J. Hope.
1997.
Biochemical typing of scrapie strains (with response from J. Collinge et al.).
Nature
386:564[Medline].
|
| 34.
|
Stahl, N.,
M. A. Baldwin,
D. B. Teplow,
L. Hood,
B. W. Gibson,
A. L. Burlingame, and S. B. Prusiner.
1993.
Structural studies of the scrapie prion protein using mass spectrometry and amino acid sequencing.
Biochemistry
32:1991-2002[CrossRef][Medline].
|
| 35.
|
Sweeney, T.,
T. Kuczius,
M. McElroy,
M. Gomerez Parada, and M. Groschup.
2000.
Molecular analysis of Irish sheep scrapie cases.
J. Gen. Virol.
81:1621-1627[Abstract/Free Full Text].
|
| 36.
|
Telling, C. G.,
P. Parchi,
S. J. De Armond,
P. Cortelli,
P. Montagna,
R. Gabizon,
J. Mastrianni,
E. Lugaresi,
P. Gambetti, and S. B. Prusiner.
1996.
Evidence for the conformation of the pathologic isoform of the prion enciphering and propagating prion diversity.
Science
274:2079-2082[Abstract/Free Full Text].
|
Journal of Virology, January 2001, p. 107-114, Vol. 75, No. 1
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.1.107-114.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Baron, T., Biacabe, A.-G.
(2007). Molecular Behaviors of "CH1641-Like" Sheep Scrapie Isolates in Ovine Transgenic Mice (TgOvPrP4). J. Virol.
81: 7230-7237
[Abstract]
[Full Text]
-
Gretzschel, A., Buschmann, A., Langeveld, J., Groschup, M. H.
(2006). Immunological characterization of abnormal prion protein from atypical scrapie cases in sheep using a panel of monoclonal antibodies. J. Gen. Virol.
87: 3715-3722
[Abstract]
[Full Text]
-
Eiden, M., Palm, G. J., Hinrichs, W., Matthey, U., Zahn, R., Groschup, M. H.
(2006). Synergistic and strain-specific effects of bovine spongiform encephalopathy and scrapie prions in the cell-free conversion of recombinant prion protein. J. Gen. Virol.
87: 3753-3761
[Abstract]
[Full Text]
-
Cordier, C., Bencsik, A., Philippe, S., Betemps, D., Ronzon, F., Calavas, D., Crozet, C., Baron, T.
(2006). Transmission and characterization of bovine spongiform encephalopathy sources in two ovine transgenic mouse lines (TgOvPrP4 and TgOvPrP59). J. Gen. Virol.
87: 3763-3771
[Abstract]
[Full Text]
-
Arima, K., Nishida, N., Sakaguchi, S., Shigematsu, K., Atarashi, R., Yamaguchi, N., Yoshikawa, D., Yoon, J., Watanabe, K., Kobayashi, N., Mouillet-Richard, S., Lehmann, S., Katamine, S.
(2005). Biological and Biochemical Characteristics of Prion Strains Conserved in Persistently Infected Cell Cultures. J. Virol.
79: 7104-7112
[Abstract]
[Full Text]
-
Novakofski, J., Brewer, M. S., Mateus-Pinilla, N., Killefer, J., McCusker, R. H.
(2005). Prion biology relevant to bovine spongiform encephalopathy. J ANIM SCI
83: 1455-1476
[Abstract]
[Full Text]
-
Baron, T., Crozet, C., Biacabe, A.-G., Philippe, S., Verchere, J., Bencsik, A., Madec, J.-Y., Calavas, D., Samarut, J.
(2004). Molecular Analysis of the Protease-Resistant Prion Protein in Scrapie and Bovine Spongiform Encephalopathy Transmitted to Ovine Transgenic and Wild-Type Mice. J. Virol.
78: 6243-6251
[Abstract]
[Full Text]
-
Lezmi, S., Martin, S., Simon, S., Comoy, E., Bencsik, A., Deslys, J.-P., Grassi, J., Jeffrey, M., Baron, T.
(2004). Comparative Molecular Analysis of the Abnormal Prion Protein in Field Scrapie Cases and Experimental Bovine Spongiform Encephalopathy in Sheep by Use of Western Blotting and Immunohistochemical Methods. J. Virol.
78: 3654-3662
[Abstract]
[Full Text]
-
Race, R. E., Raines, A., Baron, T. G. M., Miller, M. W., Jenny, A., Williams, E. S.
(2002). Comparison of Abnormal Prion Protein Glycoform Patterns from Transmissible Spongiform Encephalopathy Agent-Infected Deer, Elk, Sheep, and Cattle. J. Virol.
76: 12365-12368
[Abstract]
[Full Text]
-
Crozet, C., Flamant, F., Bencsik, A., Aubert, D., Samarut, J., Baron, T.
(2001). Efficient Transmission of Two Different Sheep Scrapie Isolates in Transgenic Mice Expressing the Ovine PrP Gene. J. Virol.
75: 5328-5334
[Abstract]
[Full Text]